A Randomized Phase II Study of NCI Supplied Cabozantinib (NSC #761968 IND #116059) versus weekly paclitaxel (NSC #673089) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Principal Investigator
Ursula Matulonis, MD
Status
Terminated
Date Opened To Accrual
November 06 2012
Date Closed to Accrual
May 05 2014
Date of Study Termination
February 09 2019
Disease Site
Gynecologic [GY]
Ovarian
Phase
II
Developmental Therapeutics
No
Primary Objective
To assess the activity of cabozantinib relative to weekly paclitaxel in patients with persistent or recurrent ovarian, fallopian tube, or primary peritoneal cancer with a log-rank test assessing progression-free survival (PFS) at 3.68 months (approximately pre-cycle 5) and 7.36 months (approximately pre-cycle 9).
Patient Population
Patients with persistent or recurrent ovarian, fallopian tube, or primary peritoneal cancer with a log-rank test assessing progression-free survival (PFS) at 3.68 months (approximately pre-cycle 5) and 7.36 months (approximately pre-cycle 9).
Target Accrual
102
Patient Study Webpage
There is no available patient study webpage available for this trial at this time.